Showing results (221-230 of 635) with videos related to
Sort By:
Pageof 64
The EMBO Journal|November 1, 1984
A molecular study of a family with Greek hereditary persistence of fetal hemoglobin and beta-thalassemiaB Giglioni, C Casini, R Mantovani, et al.Leukemia|December 10, 2013
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSPA Morotti, C Panuzzo, S Crivellaro, et al.British Journal of Haematology|August 1, 1991
A newly-characterized alpha-thalassaemia-1 deletion removes the entire alpha-like globin gene cluster in an Italian familyP Fortina, I Dianzani, A Serra, et al.Leukemia|September 23, 2006
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemiaS Branford, N C P Cross, A Hochhaus, et al.Current Molecular Medicine|February 4, 2012
BCR/ABL1 fusion transcripts generated from alternative splicing: implications for future targeted therapies in Ph+ leukaemiasP Chiarella, V Summa, S De Santis, et al.American Journal of Hematology|April 15, 1999
Acute promyelocytic leukemia after treatment for non-Hodgkin's lymphoma with drugs targeting topoisomerase IIA De Renzo, L F Santoro, R Notaro, et al.Human Genetics|January 1, 1981
Genetic regulation of gamma gene expression: study of the interaction of beta-thalassemia with heterocellular HPFHA M Soummer, U Testa, P Dujardin, et al.Acta Haematologica|January 1, 1982
Lasting Hb F reactivation and Hb A2 reduction induced by the treatment of Hodgkin's disease in a woman heterozygous for beta-thalassemia and the Swiss type of the heterocellular hereditary persistence of Hb FP Cech, U Testa, A Dubart, et al.Leukemia|November 24, 2012
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intoleranceE Jabbour, P D le Coutre, J Cortes, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Phase I study of the combination of monthly carboplatin and weekly cisplatinC Sessa, A Goldhirsch, G Martinelli, et al.Pageof 64